L-Glutamine: The Marketing vs the Gut-Barrier and Critical Illness Trial Data

L-glutamine is the most abundant amino acid in plasma and skeletal muscle. It is conditionally essential in critical illness, surgery, and burns, when consumption by the gut and immune system exceeds endogenous synthesis. The supplement industry sells it primarily for athletic recovery and "leaky gut" — neither of which is the use case where the trial evidence is strongest.

Critical illness: where the evidence began

Early observational and small trial work from European intensive care medicine showed depletion of plasma glutamine in critically ill patients, with low levels predicting mortality. Several positive randomized trials supported supplementation, and the European Society for Parenteral and Enteral Nutrition recommended parenteral glutamine in stable ICU patients on TPN. The REDOXS trial in 2013 changed the consensus — randomizing 1,223 critically ill adults with multiorgan failure to glutamine and antioxidants found a trend toward increased 28-day mortality in the glutamine arm and reached statistical significance for in-hospital and 6-month mortality [1]. The MetaPlus trial in 2014 likewise found no benefit and possible harm with enteral glutamine in the most severe ICU patients [2]. Current ICU guidelines therefore restrict glutamine to stable patients on parenteral nutrition without shock or multiorgan failure.

Short bowel syndrome and surgical recovery

In short bowel syndrome, glutamine combined with growth hormone (the Wilmore protocol) showed early promise for reducing parenteral nutrition dependence. Independent trials produced mixed results, and current expert consensus considers glutamine adjunctive but not transformative for SBS. In elective abdominal surgery, several small trials report reduced infectious complications with peri-operative parenteral glutamine, but a 2017 Cochrane review found low-certainty evidence overall [3].

Inflammatory bowel disease and IBS

For Crohn's disease, glutamine supplementation has not consistently outperformed standard enteral nutrition. For diarrhea-predominant IBS, a 2019 RCT by Zhou and colleagues found that 5 g of glutamine three times daily for 8 weeks reduced IBS symptom severity by more than half versus 6 percent on placebo, an unusually large effect [4]. Replication of this striking result is awaited.

Athletic performance and recovery: largely null

Trials of glutamine in athletes for muscle soreness, immune protection, and protein synthesis have been mostly negative. A 2008 review by Gleeson concluded that oral glutamine doses up to 30 g per day do not change post-exercise immune function or URTI rates [5]. The endurance-athlete marketing was based on early observations that glutamine falls after prolonged exercise — that fall does not translate to a benefit from supplementation, partly because plasma glutamine is also regenerated rapidly from glutamate and other precursors.

Cancer adjunct use

Glutamine has been studied for chemotherapy-induced mucositis and oxaliplatin-related neuropathy. Small trials and meta-analyses suggest modest reductions in mucositis severity at 10 g three times daily; effects on neuropathy and treatment efficacy outcomes are inconsistent. Concerns that glutamine fuels tumor metabolism have not produced clear evidence of accelerated cancer progression in clinical trials, but the question is unresolved.

Practical use

For "leaky gut" or muscle recovery in healthy adults, the evidence is thin. For chemotherapy mucositis prevention, IBS-D, and in select surgical patients, low-quality but suggestive evidence supports trial use under clinician supervision. The athletic-recovery dose of 5 to 10 g per day commonly marketed has neither demonstrated benefit nor clear harm. Critically ill patients should not receive glutamine outside protocols informed by REDOXS-era guidelines.